查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858986

核医市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 162 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球核医市场价值为 164 亿美元，预计到 2034 年将以 15.2% 的复合年增长率成长至 695 亿美元。

核子医学市场 - IMG1

核子医学的快速成长受到多种因素的推动，包括癌症和心臟疾病发病率的上升、靶向放射性核素疗法的日益普及、影像技术的不断创新以及人口老化的加剧。核子医学在现代医疗保健中发挥着至关重要的作用，它提供了一种非侵入性的诊断和治疗多种疾病的方法。放射性药物的使用能够提供传统影像技术往往无法捕捉到的分子层面的详细资讯。随着全球对精准医疗的日益重视，将放射性同位素直接输送到病变细胞的疗法因其能够最大限度地减少对健康组织的损伤而备受关注。诊疗一体化技术的进步、人工智慧驱动的医疗工具的扩展、混合影像系统的发展以及发展中国家需求的成长，都显着推动了市场的发展。诊断和标靶治疗的结合正逐渐成为该领域的核心，为进一步在全球范围内推广应用和获得监管部门的批准奠定了基础。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 164亿美元
预测值 695亿美元
复合年增长率 15.2%

2024年，诊断领域占据了66.1%的市场份额，这主要得益于对疾病早期识别需求的增长以及核成像工具的进步。 PET和SPECT等技术已成为检测癌症、心血管併发症和神经系统疾病的标准方法，其高精度结果有助于疾病分期和监测。临床上对核诊断日益增长的依赖性继续巩固了该领域的领先地位。

至2034年，心臟病学应用领域将以15.4%的复合年增长率成长。心臟疾病病例的增加，以及核子造影技术在心臟评估（例如心肌灌注研究）中的应用日益广泛，共同推动了这一稳定增长。放射性示踪剂和扫描系统的改进进一步提升了诊断效果和临床效率。

2024年，北美核医市占率达50.9%。该地区癌症和慢性疾病的高发生率，加上完善的医疗保健系统和较高的预防性诊断意识，持续推动核医学的普及应用。 PET和SPECT在医院和影像中心的广泛应用巩固了其区域领先地位。此外，病患教育的不断加强和对早期介入的重视也进一步提升了市场渗透率。

全球核子医学市场的主要参与者包括西门子医疗、康德乐医疗、Curium Pharma、波士顿科学、Jubilant Pharma、太阳製药、RadioMedix、Actinium Pharmaceuticals、Lantheus（SHINE Technologies）、GE医疗、Sirtex、Bracco、诺华、RLS Radiopharmacies和Theragenics。活跃于核子医学市场的公司正致力于透过创新、合作和垂直整合来增强其竞争优势。一项主要策略是投资研发，以开发新型放射性药物并拓展其在肿瘤学、心臟病学和神经病学领域的应用产品线。一些公司也与学术机构、医院和合约研究组织合作，以加速临床试验并扩大实际应用范围。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

  • 产业生态系分析
  • 产业影响因素
    • 成长驱动因素
      • 癌症和心血管疾病发生率不断上升
      • 对早期准确疾病诊断的需求日益增长
      • PET和SPECT影像系统的技术进步
      • 扩大放射性药物的治疗应用
      • 政府的支持性措施和资助计划
    • 产业陷阱与挑战
      • 核子医学手术和设备成本高昂。
      • 放射性同位素半衰期短且数量有限
    • 市场机会
      • 标靶放射性核种疗法的应用日益广泛
      • 混合成像技术的进步
      • 增加新型放射性药物的研究
  • 成长潜力分析
  • 报销方案
  • 监管环境
    • 北美洲
    • 欧洲
  • 技术格局
    • 当前技术趋势
    • 新兴技术
  • 管道分析
  • 未来市场趋势
  • 价值链分析
  • 波特的分析
  • PESTEL 分析
  • 差距分析

第四章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
  • 竞争定位矩阵
  • 主要市场参与者的竞争分析
  • 关键进展
    • 併购
    • 合作伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估算与预测：依产品划分，2021-2034年

  • 主要趋势
  • 诊断
    • 单光子发射电脑断层扫描（SPECT）同位素
      • TC-99m
      • I-123
      • GA-67
      • TL-201
      • 其他SPECT同位素
    • 正子断层扫描（PET）同位素
      • F-18
      • RB-82
      • 其他PET同位素
  • 疗法
    • β放射体
      • I-131
      • 卢-177
      • Y-90
      • SM-153
      • Re-186
      • 其他β发射体
    • 近距离放射治疗同位素
      • 铱-192
      • 碘-125
      • 铯-131
      • 钯-103
      • 其他近距离放射治疗同位素
    • 阿尔法发射体
      • RA-223
      • 其他α发射体

第六章：市场估算与预测：依应用领域划分，2021-2034年

  • 主要趋势
  • 神经病学
  • 心臟病学
  • 肿瘤学
  • 甲状腺
  • 肺科
  • 其他应用

第七章：市场估算与预测：依最终用途划分，2021-2034年

  • 主要趋势
  • 医院
  • 诊断中心
  • 研究机构
  • 其他最终用途

第八章：市场估算与预测：依地区划分，2021-2034年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第九章：公司简介

  • Actinium Pharmaceuticals
  • Boston Scientific
  • Bracco
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus (SHINE Technologies)
  • Novartis
  • RadioMedix
  • RLS Radiopharmacies
  • Siemens Healthineers
  • Sirtex
  • Sun Pharma
  • Theragenics
简介目录
Product Code: 12229

The Global Nuclear Medicine Market was valued at USD 16.4 billion in 2024 and is estimated to grow at a CAGR of 15.2% to reach USD 69.5 billion by 2034.

Nuclear Medicine Market - IMG1

The rapid growth is being fueled by several factors, including rising rates of cancer and heart-related illnesses, increasing use of targeted radionuclide therapies, ongoing innovation in imaging technologies, and a steadily aging population. Nuclear medicine plays a vital role in modern healthcare by offering non-invasive methods for diagnosing and treating a wide range of conditions. Using radiopharmaceuticals enables detailed molecular-level insights that traditional imaging techniques often fail to capture. With increasing global emphasis on precision medicine, therapies that deliver radioactive isotopes directly to diseased cells are gaining prominence due to their ability to minimize harm to healthy tissue. Advances in theranostics, expansion of AI-driven healthcare tools, growth in hybrid imaging systems, and a rise in demand across developing regions are significantly boosting the market. The combination of diagnostics and targeted therapies is evolving into a central focus in this field, setting the stage for further global adoption and regulatory approval.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$16.4 Billion
Forecast Value$69.5 Billion
CAGR15.2%

In 2024, the diagnostics segment held a 66.1% share, supported by growing demand for early disease identification and advancements in nuclear imaging tools. Techniques such as PET and SPECT have become standard for detecting cancer, cardiovascular complications, and neurological disorders, offering high-accuracy results that assist with staging and monitoring. This rising clinical reliance on nuclear diagnostics continues to anchor segmental dominance.

The cardiology application segment will grow at a CAGR of 15.4% through 2034. Increasing cases of heart conditions, coupled with the rising adoption of nuclear imaging for cardiac assessments such as myocardial perfusion studies, are contributing to this steady growth. Enhancements in radiotracers and scanning systems are further improving diagnostic outcomes and clinical efficiency.

North America Nuclear Medicine Market held a 50.9% share in 2024. The region's significant prevalence of cancer and chronic illnesses, combined with a well-established healthcare system and high awareness of preventive diagnostics, continues to drive the adoption of nuclear medicine. Widespread usage of PET and SPECT across hospitals and imaging centers supports regional leadership. Additionally, growing patient education and focus on early intervention are amplifying market penetration.

Key players in the Global Nuclear Medicine Market include Siemens Healthineers, Cardinal Health, Curium Pharma, Boston Scientific, Jubilant Pharma, Sun Pharma, RadioMedix, Actinium Pharmaceuticals, Lantheus (SHINE Technologies), GE Healthcare, Sirtex, Bracco, Novartis, RLS Radiopharmacies, and Theragenics. Companies active in the nuclear medicine market are focusing on a blend of innovation, partnerships, and vertical integration to reinforce their competitive edge. A primary strategy involves investing in R&D to create novel radiopharmaceuticals and expand the pipeline for oncology, cardiology, and neurology applications. Several players are also collaborating with academic institutions, hospitals, and contract research organizations to accelerate clinical trials and broaden real-world adoption.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Application trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cancer and cardiovascular diseases
      • 3.2.1.2 Increasing demand for early and accurate disease diagnosis
      • 3.2.1.3 Technological advancements in PET and SPECT imaging systems
      • 3.2.1.4 Expanding therapeutic applications of radiopharmaceuticals
      • 3.2.1.5 Supportive government initiatives and funding programs
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of nuclear medicine procedures and equipment
      • 3.2.2.2 Short half-life and limited availability of radioisotopes
    • 3.2.3 Market opportunities
      • 3.2.3.1 Growing adoption of targeted radionuclide therapies
      • 3.2.3.2 Advancements in hybrid imaging technologies
      • 3.2.3.3 Increasing research in novel radiopharmaceuticals
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
    • 3.5.1 North America
    • 3.5.2 Europe
  • 3.6 Technology landscape
    • 3.6.1 Current technological trends
    • 3.6.2 Emerging technologies
  • 3.7 Pipeline analysis
  • 3.8 Future market trends
  • 3.9 Value chain analysis
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis
  • 3.12 Gap analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers & acquisitions
    • 4.6.2 Partnerships & collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Diagnostics
    • 5.2.1 Single photon emission computed tomography (SPECT) isotopes
      • 5.2.1.1 TC-99m
      • 5.2.1.2 I-123
      • 5.2.1.3 GA-67
      • 5.2.1.4 TL-201
      • 5.2.1.5 Other SPECT isotopes
    • 5.2.2 Positron emission tomography (PET) isotopes
      • 5.2.2.1 F-18
      • 5.2.2.2 RB-82
      • 5.2.2.3 Other PET isotopes
  • 5.3 Therapeutics
    • 5.3.1 Beta emitters
      • 5.3.1.1 I-131
      • 5.3.1.2 Lu-177
      • 5.3.1.3 Y-90
      • 5.3.1.4 SM-153
      • 5.3.1.5 Re-186
      • 5.3.1.6 Other beta emitters
    • 5.3.2 Brachytherapy isotopes
      • 5.3.2.1 Iridium-192
      • 5.3.2.2 Iodine-125
      • 5.3.2.3 Cesium-131
      • 5.3.2.4 Palladium-103
      • 5.3.2.5 Other brachytherapy isotopes
    • 5.3.3 Alpha emitters
      • 5.3.3.1 RA-223
      • 5.3.3.2 Other alpha emitters

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Neurology
  • 6.3 Cardiology
  • 6.4 Oncology
  • 6.5 Thyroid
  • 6.6 Pulmonary
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic centers
  • 7.4 Research institutes
  • 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Actinium Pharmaceuticals
  • 9.2 Boston Scientific
  • 9.3 Bracco
  • 9.4 Cardinal Health
  • 9.5 Curium Pharma
  • 9.6 GE Healthcare
  • 9.7 Jubilant Pharma
  • 9.8 Lantheus (SHINE Technologies)
  • 9.9 Novartis
  • 9.10 RadioMedix
  • 9.11 RLS Radiopharmacies
  • 9.12 Siemens Healthineers
  • 9.13 Sirtex
  • 9.14 Sun Pharma
  • 9.15 Theragenics